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Abstract
Background: Progress in precision psychiatry is predicated on identifying reliable individuallevel diagnostic biomarkers. For psychosis, measures of structural and functional connectivity
could be promising biomarkers given consistent reports of dysconnectivity across psychotic
disorders using magnetic resonance imaging.
Methods: We leverage data from 4 independent cohorts of psychosis patients and controls
with observations from approximately 800 individuals. We use group-level analyses and two
supervised machine learning algorithms (support vector machines (SVM) and ridge regression)
to test within, between, and across sample classification performance of white matter and restingstate connectivity metrics.

Author Manuscript

Results: Although we replicate group-level differences in brain connectivity, individual-level
classification was suboptimal. Classification performance within sample was variable across folds
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(highest AUC range= 0.30) and across datasets (average SVM AUC range= 0.50; average ridge
regression AUC range= 0.18). Classification performance between samples was similarly variable
or resulted in AUC values around 0.65, indicating a lack of model generalizability. Furthermore,
collapsing across samples (rsfMRI N=888, DTI N=860) did not improve model performance
(maximal AUC= 0.67). Ridge regression models generally outperformed SVM models, although
classification performance was still suboptimal in terms of clinical relevance. Adjusting for
demographic covariates did not greatly affect results.
Conclusions: Connectivity measures were not suitable as diagnostic biomarkers for psychosis
as assessed in the current study. Our results do not negate that other approaches may be more
successful although it is clear that a systematic approach to individual-level classification with
large independent validation samples is necessary to properly vet neuroimaging features as
diagnostic biomarkers.

Author Manuscript
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Introduction

Author Manuscript

Decisions related to the diagnosis and treatment of psychotic disorders like schizophrenia,
bipolar disorder, and schizoaffective disorder, are currently dependent on patient report,
behavioral observation, and clinical judgment rather than objective laboratory measures(1).
Unfortunately, reliance on phenomenology limits the field’s attempts to join the
precision medicine revolution(2) and likely contributes to the underinvestment in novel
pharmacological treatments for psychotic illness(3). What is needed are biomarkers indexing
core biological processes that more precisely predict clinical outcomes and provide novel
insights into the pathophysiology of psychosis, psychosis risk, and psychosis treatment(4).

Author Manuscript

Neuroimaging measures acquired via magnetic resonance imaging (MRI) could serve
as such biomarkers by acting as objective endpoints to evaluate treatment response
or prognostic accuracy(5). Brain connectivity measures(6–8) are particularly promising
given consistent reports of aberrant functional and structural connectivity across psychotic
disorders(9–14) and at various stages of illness(15–19). Psychosis-related disruptions
in functional connectivity (measured by resting state functional MRI-rsfMRI(20)) often
include hypo-connectivity within and between large-scale cortical networks(6), especially
those involving frontal and temporal cortex, whereas psychosis-related disruptions in
structural connectivity (measured by Diffusion Tensor Imaging-DTI(21)) include brain-wide
reductions in fractional anisotropy (FA), an indirect measure of white matter integrity(22).
In fact, the two markers themselves are inter-related in both psychotic and healthy
individuals(23, 24).
Although findings suggest that connectivity measures have great potential as diagnostic
biomarkers for psychosis, conclusions related to their clinical utility remains unclear.
Currently, psychotic dysconnectivity is primarily reported at the group level, however a
successful biomarker should discriminate cases from controls at the individual level(25–27).
Machine learning may bridge this disconnect(28, 29) by providing objective measures of
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individual-level classification while integrating large amounts of data that are characteristic
of MRI connectivity analyses. While machine learning methods have been used to validate
neuroimaging biomarkers in psychiatry, a recent review by Scheinost and colleagues(30)
highlighted non-trivial shortcomings in their current implementation, including lack of
consideration for covariate effects, failure to keep training and testing data independent,
and lack of reporting metrics beyond accuracy to evaluate classification performance.
Concerns about sample size and the absence of out-of-sample validation were also
reported. Indeed, connectivity studies using machine learning seldom exceed 100 people
per group, with larger sample sizes often failing to improve classification performance(28,
29, 31). Furthermore, reported classification accuracies are variable, reaching as high as
100%(28, 32, 33) without independent datasets for validation(34). DTI measures are also
underrepresented in current studies(33, 35, 36), making their diagnostic utility unclear.

Author Manuscript

Our goal is to evaluate functional (rsfMRI) and structural (DTI) connectivity measures,
separately and combined, as diagnostic biomarkers for psychosis(30) while systematically
addressing the aforementioned concerns regarding machine learning analyses. To achieve
this, we use four independent datasets with neuroimaging data. Initially, we perform
group-level univariate analyses to confirm the presence of psychotic dysconnectivity
in our samples. Next, we leverage our access to multiple independent datasets by
implementing a multi-level data analysis strategy to evaluate individual-level classification
performance. First, we perform within sample classification to determine whether functional
and structural connectivity measures could consistently classify individuals regardless of
variations in sample characteristics or data collection procedures(37). Second, we evaluate
generalizability by building models in one dataset and testing in the remaining three,
satisfying the requirement by the Psychiatric Neuroimaging Working Group of the American
Psychiatric Association (APA) that biomarkers be validated in at least two independent
samples(38). Third, we address key factors that could affect classification performance
including demographic covariates, algorithm choice, and sample size. Finally, we share
our feature sets and models so that others can implement their preferred machine learning
technique or predict diagnostic status in their own samples.

Author Manuscript

Materials and Methods
Subjects

Author Manuscript

Participants were individuals with and without psychosis with rsfMRI and/or DTI data from
4 independent samples (Table 1): one from the Icahn School of Medicine at Mount Sinai
(ISMMS), two from the Olin Center for Neuropsychiatric Research (Olin and a subset of
BSNIP-2), and one collected at the Olin Center and the University of Maryland School of
Medicine (BSNIP-1). Recruitment and scanning procedures for each sample are described
in the Supplemental Materials and Supplementary Table 1. Most psychosis cases were
mid-course and stably medicated.
Feature Generation
rsfMRI.—MRIQC v0.15.0(39) was used to generate visual reports and quality control
(QC) metrics for rsfMRI data in each sample (Supplementary Table 2 and Supplemental
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Materials). Pre-processing was performed with fMRIPrep(40), version 1.3.2. Squares and
derivatives of six motion parameters, frame-wise displacement, DVARS, and anatomical
CompCor components(41) were regressed from the data. Residual mean time series were
extracted from cortical and sub-cortical regions (N=250) using the Brainnetome atlas(42).
Features for machine learning were unique values from the 250×250 matrix of correlation
coefficients (converted to z-scores (z=.5×ln(1+r)/(1−r))) between the time courses for each
pair of nodes for each subject. A second set of features was generated by residualizing for
age, sex, and site (BSNIP-1 only). Further detail is noted in Supplemental Materials.

Author Manuscript

DTI.—Diffusion-weighted images were processed using FSL(43), version 5.0.10.
Preprocessing included brain extraction(44), motion and eddy current correction(45), and
tensor fitting, resulting in individual FA maps. A summary of QC metrics for each
sample is listed in Supplementary Table 2. Preprocessed FA maps passing QC procedures
(see Supplemental Methods) were fed into the Tract-Based Spatial Statistics (TBSS)
pipeline(46); for each participant, average FA was calculated for 20 tracts from the John’s
Hopkins University white matter tractography atlas(47). A second set of features was
generated by residualizing for age, sex, and site (BSNIP-1 only). Further detail is noted
in Supplemental Materials.
Group-level Univariate Analysis

Author Manuscript

We tested between-group differences in rsfMRI and DTI features for each sample using
standard univariate null hypothesis testing methods. For rsfMRI, we performed two-sample
t-tests comparing connectivity between each pair of nodes using the FSL Nets Analysis
package, version 0.6.3 (http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/FSLNets). Significance testing
was performed using permutation tests via nets_glm (48). For DTI, we performed twosample t-tests comparing FA values for each tract, considering FDR corrected p-values(49) <
0.05 as significant.
For each modality, we also quantified the aggregate effect across samples using randomeffects inverse-variance weighted meta-analyses in R (metafor package, version 2.1–0
http://www.metafor-project.org/). For rsfMRI, we included connections showing significant
differences between psychosis cases and healthy participants in one or more samples. To
quantify how similar findings were in each sample, we performed Pearson correlations
between case-control effect sizes in each pair of studies for both functional and structural
connectivity measures.
Supervised Machine Learning

Author Manuscript

We used two machine learning algorithms, linear support vector machines (SVMs) and
L2 logistic regression (ridge regression). For each algorithm, parameter optimization
was performed using a grid search and nested cross validation (with 5 folds for both
the outer and inner loops) over a range of values chosen to span several orders
of magnitude, large enough to identify the optimal parameter space. SVMs classify
individuals by projecting features into a multi-dimensional feature space and constructing
a hyperplane that maximizes distances between data points of opposing groups by
minimizing a cost function(50). Nested cross validation was performed with cost values
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[1,2,5,10,25,50,100,200,500,750,1000,5000]. Results were reported for models with a
cost of 1 given that classification accuracies were not altered when optimizing the cost
parameter. Ridge regression is a regularized form of logistic regression that mitigates multicollinearity(51) by using a regularization parameter (λ). Optimization of λ was performed
over 80 linearly spaced values between 1 and 5000. Regression model results are reported
for lambda values that yielded the minimum mean cross-validated RMSE over training
folds. In practice we found a high value of lambda was needed to sufficiently penalize the
model. Training and testing datasets for all analyses were identical for each algorithm and
covariate condition to ensure comparability.

Author Manuscript

For each covariate and algorithm condition, we considered features from each modality
in separate and combined models and implemented three levels of analysis (outlined in
Supplementary Figure 1). First, we evaluated within sample classification performance for
each dataset using k-fold (k=5) cross-validation implemented with the “createDataPartition”
function from the Caret package in R (52). Data was partitioned into training and testing
folds using random selection with p = .8 (i.e. 80% of the data was used for training, 20%
for testing), while preserving the proportion of psychosis cases to controls in the overall
sample within each fold. Next, we tested model generalizability by systematically using each
sample as a training dataset and testing classification performance on the remaining samples
separately. Finally, we evaluated the effect of sample size on classification performance by
combining all samples into one dataset and performing k-fold (k=5) cross-validation using
the same procedures as within-sample classification. Note that in the combined sample case,
we did not use sample as a confounding covariate due to concern that this could induce
spurious associations (via condition on a collider (53)) since site is not randomly assigned
and could be associated with psychological or biological factors (e.g. common effects of
socioeconomic status). Classification performance for all models was evaluated using the
area under the receiver operating curve (AUC of the ROC), a comprehensive measure of
algorithm discriminability that is threshold-independent and results in a singular measure
by which to compare classification success. We also report accuracy, sensitivity, specificity,
positive predictive value (PPV), and negative predictive value (NPV) from the midpoint of
the ROC curve to compare our results to studies without ROC-based measures.

Author Manuscript

Results
Group-level Psychotic Dysconnectivity

Author Manuscript

Psychosis cases showed wide-spread reductions in resting state functional connectivity
compared to heathy participants, but results were variable across samples (Figure 1 and
Supplementary Figure 2 and 3). The ISMMS sample showed few significant case-control
differences, with most disrupted connections linking the supplementary motor (SM) and
default mode networks (DMN). In contrast, case-control differences in the Olin sample were
dominated by connections within and between cognitive control networks [DMN, ventral
attention network (VAN), and salience (SAL)] and between cognitive control networks and
the auditory and SM networks. Case-control differences in BSNIP-1 were between visual
networks and both lower-order sensory and higher-order association networks. BSNIP-1
psychosis cases also showed stronger connectivity than healthy participants in limbic and
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DMN networks, although only when residualizing features for covariates such as age,
sex, and site. Lastly, case-control differences in BSNIP-2 were dominated by reductions
in connectivity between sensory networks (visual and SM/auditory and SM) and between
the DMN and the SAL and VAN networks. The aggregate effect across datasets included
most connections that were weaker in psychosis in all four samples. In-scanner motion was
significantly higher in cases than in healthy participants (ISMMS: t(106)= −2.31, p= 0.02;
Olin: t(205.77)= −1.98, p= 0.05; BSNIP-1: t(250.96)= −4.43, p= 1.40 × 10−5; BSNIP-2:
t(113.02)= −2.52, p= 0.01), although motion effects were regressed from time series before
group-level analyses.

Author Manuscript

Psychosis cases also showed reductions in structural connectivity, with lower FA values than
healthy participants in most white matter tracts (Figures 1 and Supplementary Figure 2).
Effect sizes varied across samples (Supplementary Figure 3), although the aggregate effect
included most white matter tracts. There were no significant group differences in in-scanner
motion (average root mean square difference from the first volume)(ISMMS: t(177)= −0.51,
p= 0.61; Olin: t(274)= −1.04, p= 0.30; BSNIP-2: t(103)= −0.29, p= 0.77); as we obtained
preprocessed BSNIP-1 data that matched our standardized pipeline, the sample did not
include the necessary information to obtain motion estimates).
Inclusion of demographic covariates (age, sex, and site (where appropriate)) did not
significantly alter the pattern of group-wise results for either modality, except for BSNIP-1,
where there was a large increase in the number of significantly weaker functional
connections in the psychosis group, likely given the inclusion of site as a covariate.
Individual-level Classification Within-Sample Classification

Author Manuscript

SVM.—Classification performance was modality- and sample-specific (Figure 2A and
Supplementary Table 3). rsfMRI model performance varied widely across samples (AUC
range 0.26–0.73). DTI models were more consistent across samples but performed poorly
(AUC values mostly < 0.50). Combining modalities did not improve either performance
or variability. Model feature weights were also inconsistent across samples (Supplementary
Figure 4A). For example, connections between the SM and limbic network, which had the
largest positive weights in the rsfMRI model constructed in the ISMMS sample, were close
to zero for models built in the Olin and BSNIP-2 samples, and negative in the BSNIP-1
sample. Within samples, fold-wise variability was also apparent with non-trivial standard
deviations in AUC values and feature weights. Adjusting for covariates did not greatly affect
classification performance (Supplementary Figure 5A and Supplementary Table 3) or feature
weightings (Supplementary Figure 6A).

Author Manuscript

Ridge Regression.—Classification performance was similar to, or numerically better
than, SVM performance (Figure 2B and Supplementary Table 3) (AUC values generally
above 0.50). However, variability in performance across samples for each modality
persisted. Inconsistency in feature weightings across datasets (Supplementary Figure 4B)
and fold-wise variability in AUC also persisted. Adjusting for covariates did not globally
affect results (Supplementary Figure 5B,6B, and Supplementary Table 3).
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SVM.—Figure 3A shows classification performance for each sample as a training set (rows)
and the remaining samples as independent test sets (colored bars/lines within panels) (also
see Supplementary Table 4a). Performance was either inconsistent across testing datasets or
poor regardless of the modality or dataset used for training. For example, rsfMRI models
trained in BSNIP-2 had the most consistent performance across testing sets, although no
AUC value exceeded 0.65. Classification success was also heavily dependent on which
dataset was used to train the model. For example, BSNIP-1 AUCs for rsfMRI models
were 0.41 when the model was trained in the ISMMS sample, 0.50 when trained in the
Olin sample, and 0.65 when trained in the BSNIP-2 sample. Again, combining modalities
did not result in superior model performance and results were unaffected by covariates
(Supplementary Figure 7A and Supplementary Table 4a).

Author Manuscript

Ridge Regression.—Classification performance was similar to, or numerically better
than that observed for SVM (Figure 3B and Supplementary Table 4b) with AUC values
improving most for models using both feature modalities (compare right most panels in
Figures 3B and 3A). While variability across datasets within a test set and variability within
a test set across training sets was reduced, performance was still suboptimal with most
AUC values below 0.70. Results were unaffected by adjusting for covariates (Supplementary
Figure 7B Supplementary Table 4b).
Across-sample Classification

Author Manuscript

SVM.—Pooling data across samples resulted in ~500 psychosis cases and ~300 healthy
participants (rsfMRI: HC=362, psychosis = 525; DTI: HCs = 353, Psychosis=506;
rsfMRI+DTI: HC=287, Psychosis=413; see also Supplemental Table 5). Despite increases in
sample size, there was no numerical advantage over models built within a dataset (Figure
4,Supplementary Figure 8, and Supplementary Table 6). Using features residualized for
covariates reduced rsfMRI model performance (AUC=0.73 to AUC=0.53) and improved
combined modality model performance (AUC=0.29 to AUC=0.50). DTI model performance
was not dependent on adjusting for covariates.
Ridge Regression.—Models using ridge regression performed equally across modalities
with AUC values below 0.70 and were unaffected by covariate condition (gray bars in Figure
4, Supplementary Figure 8, and Supplementary Table 6).

Discussion
Author Manuscript

Successful biomarkers are reproducible, reliably identify case-control status at the individual
level across samples(37), and generalize to independent samples(38). The MRI-based
functional and structural connectivity measures examined here did not meet these standards,
indicating that these measures are unsuitable for individual subject-level classification
using SVM and ridge regression. As we describe below, it is possible that advances
in acquisition or different classification algorithms (e.g. nonlinear) could improve the
utility of connectivity measures as biomarkers for psychosis. Furthermore, given the
myriad of machine learning approaches currently available and the rapid pace of
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algorithm development, we provide the feature sets utilized in these analyses to the
research community (https://doi.org/10.5281/zenodo.4374644) in order to facilitate the
direct comparison of classification methodologies. Our hope is that these data can facilitate
new analytic approaches which may lead to more optimistic outcomes for connectivitybased psychosis biomarkers.

Author Manuscript

Despite confirming that functional and structural dysconnectivity are features of psychosis
via group-level univariate analyses, we found substantial heterogeneity across samples
(Figure 1; Supplementary Figure 2 and 3). Across-sample heterogeneity has major
implications for biological models of psychosis based on neuroimaging data. For example,
interpretation of group differences in functional connectivity would likely result in different
conclusions about the nature of psychosis, from a disorder involving primarily sensory
networks to one involving various higher order association networks. Yet, each of our
findings is not unique and has been reported in other independent studies(6, 54–57) . Group
differences in structural connectivity were more stable, although effect sizes were sampledependent (Figure 1; Supplementary Figure 2 and 3). Effect size variability, however, was
consistent with individual studies included in the recent ENIGMA meta-analysis(22). For
both functional and structural connectivity, within-sample classification provided further
evidence of sample heterogeneity as there was little overlap in the features utilized when
building models in one sample vs. another. Variability across studies in either context
could arise from multiple sources including methodological and/or biological variation.
We attempted to minimize both by implementing nearly identical analytic pipelines and
accounting for confounding factors such as age and sex. Additional factors, such as scanning
protocols or other subject-specific factors (e.g. type of individuals included in the patient or
control group) may have also contributed.

Author Manuscript

Results of within sample classification provided valuable information regarding the
consistency of predicting an individual’s case-control status, even when capitalizing on
sample-specific features. While we replicated within sample classification performance in
other studies with AUC values as high as 0.80(58), this performance did not generalize
across datasets with AUC values in some samples at or below 0.50. Classification
performance was likewise inconsistent when building models within a dataset using 5-fold
cross validation. For each dataset, AUC values over the five folds varied as little as 0.06 to
as much as 0.38 (Supplementary Figure 9 and Supplementary Table 3), suggesting model
performance was highly dependent on the exact participants included in the training and
testing datasets.

Author Manuscript

Between sample classification performance is arguably the most important estimator of
model validation and generalizability and is critical for future clinical applications(38).
Our results did not wholly support the generalizability of the examined features. Some
between sample models had modest performance (AUC approaching 0.80), but this was
not observed across testing datasets for a given training dataset. Models using ridge
regression and rsfMRI features were more consistent both across testing sets for a given
training set and for a given testing set across training sets, although most AUC values
were below .7. While these AUC values were above chance and their consistency is
promising, this performance unfortunately falls short of requirements for practically useful

Biol Psychiatry Cogn Neurosci Neuroimaging. Author manuscript; available in PMC 2022 December 01.

Rodrigue et al.

Page 9

Author Manuscript

and clinically relevant biomarkers. Furthermore, our between -sample classification results
do not appear to be unique as we replicated two prior studies which reported similarly
suboptimal classification performance when attempting to validate rsfMRI-derived models
in independent datasets(59, 60).

Author Manuscript

Several methodological issues could have influenced the present findings, many of which we
addressed directly. One was the effect of sample size. Both real and simulated data show
that smaller sample sizes result in highly variable accuracy estimates with substantial errors
(~10%)(61), which some suggest can be remedied by increasing the number of observations
despite likely increases in heterogeneity(62). In our study, models utilizing all available
participants (approximately 800 individuals) performed similar to, or slightly worse than,
models built within datasets (Figure 4), although fold-wise stability was numerically better
than that for within sample classification. Given the high level of inter-individual variation
in our samples, it may be necessary to include vary large samples akin to those used in
genetic studies for individual-level classification to be successful. This is particularly true
if psychotic disorders are so heterogeneous that only small sub-samples share the same
features.

Author Manuscript

Including a singular diagnosis like schizophrenia, as is common in most studies(63), may
qualify as such a sub-sample. The present study was designed under the premise that a
cross-diagnostic sample would improve the likelihood of discovering a marker for psychosis
itself, given robust evidence that 1) traditional diagnoses do not reflect biologically distinct
categories(64, 65) and 2) core psychotic features (cognitive-behavioral disorganization,
hallucinations, delusions, etc.) may reflect a more homogeneous biological substrate than
clinical diagnosis per se(65). This premise appears to be supported by a post-hoc analysis
where we performed within-sample classification with our most promising metrics (ridgeregression and rsfMRI features) in our largest cohort (BSNIP-1) with only schizophrenia
participants in the patient group. While performance was slightly better, it was still below .7
and fold-wise variability was increased (see supplemental Figure 10). We do not, however,
negate the possibility that connectivity measures may be more suitable for predicting
different criteria, be it continuous metrics (e.g. symptom severity, functional outcome,
etc.) or other types of classification structures like the biotypes developed by the BSNIP
consortium(65, 66). Changes in predicted targets may also ease projected sample size
requirements mentioned previously. While we were unable to test these kinds of hypotheses
given the variability and/or lack of data available for each sample, this should be a focus of
future work.

Author Manuscript

An additional consideration was the inclusion of covariates. Adjusting for covariates did
not largely alter results. The exception was for models built across samples using rsfMRI
or combined features (a decrease and increase in AUC values respectively), although the
difference was minimal and only apparent when using the SVM algorithm (Figure 4;
Supplementary Figure 8). Algorithm choice appeared to influence performance in other
classification contexts in that ridge regression performance metrics were often more stable
across datasets and numerically higher than those achieved using SVM. However, using
ridge regression did not resolve issues of variability or suboptimal performance to a
sufficient degree to warrant that connectivity metrics are valid biomarkers for psychosis.
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We chose the current algorithms because they have shown promise in previous studies
using machine learning and MRI features in schizophrenia and psychosis(67–69). We do not
negate that more complex algorithms (e.g. non-linear models) or machine learning methods,
like deep learning, may better classify individuals with psychosis. However, Schultz and
colleagues(70) showed that simple linear models perform on par with complex techniques
when using neuroimaging data for individual-level classification. Furthermore, increasingly
complex models are more likely to overfit a singular dataset and subsequently less likely to
translate to independent data.

Author Manuscript
Author Manuscript

Lastly, combining modalities did not consistently improve classification performance,
regardless of the training/testing strategy, and despite evidence of different imaging data
capturing unique and additive aspects of psychopathology(71, 72). This result was similar
to those of Guo et al. (2018) which showed similar classification performance between
rsfMRI features alone and a fusion of features from multiple modalities (73). Alternatively,
it could be that different features altogether would perform better. We chose the features
here because they were the most commonly used measures in the literature and there was
consistent evidence for case-control differentiation at the group level with adequate sample
sizes. For example, tractography measures may be better suited for classification using DTI
data, however, we though it important to vet one of the most robustly demonstrated potential
biomarkers provided via the ENIGMA meta-analysis(22). Given that those potential
biomarkers were largely unsuccessful, it begs the question of what large differences at
the group level tells us about individual-level prediction. Additionally for resting state, we
used the Brainnetome atlas given reports that it may be superior to measures constructed
using anatomical parcellations(74), whole-brain, or graph-based methods(58). As there were
already a large number of model comparisons, we did not address the effect of feature
selection. We do, however, recognize its importance and suggest that it and alternative
feature types be the focus of future work.
In summary, leveraging data from over 800 individuals allowed us to confirm that measures
of aberrant functional and structural connectivity are indeed present in psychosis at the
group level(9, 15), but were not suitable for individual-level classification, at least with the
algorithms and measures used here. Variability observed at both levels of analysis suggest
that the field must focus on identifying measures that are more reproducible across sites
and datasets. While it is possible that successful connectivity biomarkers may result from
future innovation in technology, analytic pipelines, or perhaps other techniques that were not
utilized in our analysis, neuroimaging researchers and clinicians awaiting useful biomarkers
of the type they could employ to make consequential, person-level diagnoses should remain
cautious.
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Figure 1. Group-wise Differences in Connectivity between Psychosis Cases and Healthy
Participants: Non-Residualized Features.

Author Manuscript
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Reported N’s are the number of healthy participants and number of psychosis cases
respectively. For rsfMRI (top), red lines show significant reductions in functional
connectivity between nodes in psychosis cases compared to healthy participants for each
sample (after permutation testing) and for the metanalysis across all samples (after FDR
correction). To improve interpretability, Brainnentome nodes were assigned to one of the
17 networks defined in Yeo et al.(75) (https://github.com/ThomasYeoLab/CBIG/tree/master/
stable_projects/brain_parcellation/Schaefer2018_LocalGlobal). See supplemental Table 7
for node order in circular plots. We further subdivided the “NONE” category into
subcortical regions (AMY, HIPP, BG, and THALAMUS) for clarity. For DTI (bottom),
bars show the Cohen’s d effect size for t-tests performed for the 20 white matter
tracts in each sample and the metanalysis (error bars are confidence intervals). Negative
effect sizes (pink/red) indicate psychosis cases FA < healthy participant FA. Darker
shades indicate significant differences (FDR-corrected). Positive effect sizes (blue)
indicate psychosis cases FA > healthy participant FA. rsfMRI= resting state MRI, DTI=
Diffusion Tensor Imaging, SM=Supplementary Motor, DMN=Default Mode Network,
DAN=Dorsal Attention Network, VAN=Ventral Attention Network, SAL=Salience Network,
AMY=Amygdala, HIPP=Hippocampus, BG=Basal Ganglia, ATR=Anterior Thalamic
Radiation, CgC=Cingulum Cortex, CgH=Cingulum Hippocampus, CST=Corticospinal
Tract, Fmaj=Forceps major, Fmin=Forceps minor, IFOF=Inferior Fronto-Occipital
Fasciculus, ILF=Inferior Longitudinal Fasciculus, SLF=Superior Longitudinal Fasciculus,
tSLF=Superior Longitudinal Fasciculus Temporal Part, UF=Uncinate Fasciculus.

Biol Psychiatry Cogn Neurosci Neuroimaging. Author manuscript; available in PMC 2022 December 01.

Rodrigue et al.

Page 16

Author Manuscript
Author Manuscript

Figure 2. Within Sample Classification Results: Non-Residualized Features.
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A. Performance profiles for the SVM algorithm and each feature modality. Colors
correspond to samples. Bars show AUC (overall algorithm performance), while lines show
point estimates from the midpoint of the ROC curve. Values on the y-axis are average
values over 5 folds and error bars represent the standard deviation over folds. Values
are for models using non-residualized features. Results for models using residualized
features are shown in Supplementary Figure 5A and are largely similar. B. Same as A.
but for ridge regression. Results for models using residualized features are shown in
Supplementary Figure 5B. rsfMRI=resting state functional MRI, DTI=Diffusion Tensor
Imaging, PPV=Positive Predictive Value, NPV=Negative Predictive Value, AUC=Area
Under the Curve.
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Figure 3. Between Sample Classification Results: Non-Residualized Features.
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A. SVM performance profiles for between-sample sample classification for each feature
modality (columns) when each sample is used as the training sample (rows). Each bar
and line within a panel represents an independent testing sample for each training sample
(n=3). Values are for models using non-residualized features; results for models using
residualized features are shown in Supplementary Figure 7A and are largely similar B.
Same as A but for the ridge regression algorithm. Again, models using residualized features
are similar and shown in Supplementary Figure 7B. rsfMRI=resting state functional MRI,
DTI=Diffusion Tensor Imaging, PPV=Positive Predictive Value, NPV=Negative Predictive
Value, AUC=Area Under the Curve.
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Figure 4. Across Sample Classification.

Bars are average AUC values over five folds with error bars representing the standard
deviation over folds. Gray bars show across sample classification for each machine learning
algorithm using residualized and non-residualized features compared to within sample
classification for each dataset and each modality (colored bars). rsfMRI=resting state
functional MRI, DTI=Diffusion Tensor Imaging, AUC=Area Under the Curve.
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